Search Results - "Freedman, MS"

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis by Das, J, Snowden, JA, Burman, J, Freedman, MS, Atkins, H, Bowman, M, Burt, RK, Saccardi, R, Innocenti, C, Mistry, S, Laud, PJ, Jessop, H, Sharrack, B

“…Background: Autologous haematopoietic stem cell transplantation (AHSCT) is an effective treatment for patients with multiple sclerosis (MS) who have highly…”
Get full text

Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

“…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
Get full text

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis by Freedman, MS, Wolinsky, JS, Truffinet, P, Comi, G, Kappos, L, Miller, AE, Olsson, TP, Benamor, M, Chambers, S, O’Connor, PW

“…Background Teriflunomide is a once-daily oral immunomodulator for the treatment of relapsing−remitting MS. Objective To evaluate the safety and tolerability of…”
Get full text

Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis by Thebault, Simon, Abdoli, Mohammad, Fereshtehnejad, Seyed-Mohammad, Tessier, Daniel, Tabard-Cossa, Vincent, Freedman, Mark S.

“…Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS). Our objective was to evaluate the prognostic value of…”
Get full text

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension by Kapoor, Raju, Chang, Ih, Deykin, Aaron, Forrestal, Fiona, Lucas, Nisha, Yu, Bei, Arnold, Douglas L, Freedman, Mark S, Hartung, Hans-Peter, Jeffery, Douglas, Sellebjerg, Finn, Cadavid, Diego, Mikol, Dan, Bartholomé, Emmanuel, D'Hooghe, Marie, Devonshire, Virginia, Grand'Maison, François, Jacques, François, Lapierre, Yves, Morrow, Sarah, Stetkarova, Ivana, Talabova, Marika, Frederiksen, Jette, Kant, Matthias, Petersen, Thor, Eralinna, Juha-Pekka, Brassat, David, Brochet, Bruno, Vermersch, Patrick, Vukusi, Sandra, Baum, Karl, Maeurer, Mathias, Meuth, Sven, Hardiman, Orla, Achiron, Anat, Karussis, Dimitrios, Bergamaschi, Roberto, Grimaldi, Luigi, Salvetti, Marco, Scarpini, Elio, Sola, Patrizia, Zaffaroni, Mauro, Frequin, Stephan, Hupperts, Raymond, Killestein, Joep, Schrijver, Hans, van Munster, Erik, Drozdowski, Wieslaw, Fryze, Waldemar, Klodowska-Duda, Gabriela, Motta, Ewa, Podemski, Ryszard, Selmaj, Krzysztof, Stepien, Adam, Tutaj, Andrzej, Boyko, Alexey, Escartin, Antonio, Garcia-Merino, Antonio, Hernandez Perez, Miguel Angel, Ayuso, Guillermo Izquierdo, Lallana, José Meca, Gairin, Xavier Montalban, Gunnarsson, Martin, Roshanisefat, Homayoun, Sundstrom, Peter, Gran, Bruno, Kapoor, Raju, Mattison, Paul, Pearson, Owen, Rashid, Waqar, Rog, David, Silber, Eli, Bandari, Daniel, Camac, Ann, Cohan, Stanley, Fabian, Michelle, Florin, Jack, Freedman, Steven, Garwacki, Dennis, Goldman, Myla, Harrison, Daniel, Herrman, Craig, Huang, Deren, Jeffery, Douglas, Kamin, Stephen, Langer-Gould, Annette, Mattson, David, Miller, Tamara, Moses, Harold, Muley, Suraj, Nielsen, Allen, Pardo, Gabriel, Picone, MaryAnn, Robertson, Derrick, Sheppard, Christopher, Thrower, Ben, Twyman, Cary, Waubant, Emmanuelle, Yadav, Vijayshree, Zabad, Rana

“…Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple…”
Get full text

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis by O'Connor, Paul, Wolinsky, Jerry S, Confavreux, Christian, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Benzerdjeb, Hadj, Truffinet, Philippe, Wang, Lin, Miller, Aaron, Freedman, Mark S

“…In this trial, teriflunomide reduced annualized relapse rates and disability progression over 108 weeks of treatment in patients with relapsing MS, although…”
Get full text

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial by Confavreux, Christian, Prof, O'Connor, Paul, Prof, Comi, Giancarlo, Prof, Freedman, Mark S, Prof, Miller, Aaron E, Prof, Olsson, Tomas P, Prof, Wolinsky, Jerry S, Prof, Bagulho, Teresa, MD, Delhay, Jean-Luc, MD, Dukovic, Deborah, MS, Truffinet, Philippe, MD, Kappos, Ludwig, Prof

“…Summary Background Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing–remitting multiple sclerosis. We aimed…”
Get full text

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial by Miller, Aaron E, Prof, Wolinsky, Jerry S, Prof, Kappos, Ludwig, MD, Comi, Giancarlo, Prof, Freedman, Mark S, Prof, Olsson, Tomas P, Prof, Bauer, Deborah, MS, Benamor, Myriam, MD, Truffinet, Philippe, MD, O'Connor, Paul W, Prof

“…Summary Background Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting multiple sclerosis. We aimed to assess…”
Get full text

Neurofilaments as biomarkers in neurological disorders — towards clinical application by Khalil, Michael, Teunissen, Charlotte E., Lehmann, Sylvain, Otto, Markus, Piehl, Fredrik, Ziemssen, Tjalf, Bittner, Stefan, Sormani, Maria Pia, Gattringer, Thomas, Abu-Rumeileh, Samir, Thebault, Simon, Abdelhak, Ahmed, Green, Ari, Benkert, Pascal, Kappos, Ludwig, Comabella, Manuel, Tumani, Hayrettin, Freedman, Mark S., Petzold, Axel, Blennow, Kaj, Zetterberg, Henrik, Leppert, David, Kuhle, Jens

“…Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-axonal injury. The advent of highly sensitive analytical platforms that…”
Get full text

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial by Uccelli, Antonio, Laroni, Alice, Ali, Rehiana, Battaglia, Mario Alberto, Blinkenberg, Morten, Brundin, Lou, Clanet, Michel, Fernandez, Oscar, Marriott, James, Muraro, Paolo, Nabavi, Seyed Massood, Oliveri, Roberto S, Radue, Ernst, Ramo Tello, Cristina, Schiavetti, Irene, Sellner, Johann, Sorensen, Per Soelberg, Sormani, Maria Pia, Wuerfel, Jens Thomas, Freedman, Mark S, Aghdami, Naser, Agüera-Morales, Eduardo, Ali, Rehiana, Allan, David, Arab, Leila, Battaglia, Mario, Berry, Isabelle, Blinkenberg, Morten, Bonetti, Bruno, Brundin, Lou, Capelli, Chiara, Castellan, Lucio, Cellerino, Maria, Cencioni, Maria Teresa, Clanet, Michel, Comi, Giancarlo, Courtman, David, Dazzi, Francesco, Fischer-Nielsen, Anne, Fernandez, Oscar, Fernandez, Victoria, Freedman, Mark S., Furlan, Roberto, Gimona, Mario, Gualandi, Francesca, Guan, Qingdong, Iacobaeus, Ellen, Inglese, Matilde, Introna, Martino, Izquierdo, Guillermo, Karimi, Shahedeh, Laroni, Alice, Le Blanc, Katarina, Loaiza, Sandra, Mallik, Shahrukh, Marley, Stephen, Marrie, Ruth Ann, Marriot, James, Martino, Gianvito, Nabavi, Seyed Massood, Miller, David, Muraro, Paolo A., Nicholas, Richard, Oliveri, Roberto S, Orengo, Giovanni, Palanicawande, Renuka, Pardini, Matteo, Radue, Ernst W, Ramo Tello, Cristina, Rush, Carolina, Schiavetti, Irene, Sellner, Johann, Sensebe, Luc, Soelberg Sorensen, Per, Sormani, Maria Pia, Strunk, Dirk, Szwajcer, David, Thalamas, Claire, Uccelli, Antonio, Wuerfel, Jens Thomas

“…Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis…”
Get full text

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial by Vermersch, Patrick, Czlonkowska, Anna, Grimaldi, Luigi ME, Confavreux, Christian, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Benamor, Myriam, Bauer, Deborah, Truffinet, Philippe, Church, Meg, Miller, Aaron E, Wolinsky, Jerry S, Freedman, Mark S, O’Connor, Paul

“…Background: In previous studies, teriflunomide significantly reduced the annualised relapse rate (ARR) and disability progression. Objective: This phase 3,…”
Get full text

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial by Olsson, Tomas, Boster, Aaron, Fernández, Óscar, Freedman, Mark S, Pozzilli, Carlo, Bach, Doris, Berkani, Ouali, Mueller, Markus S, Sidorenko, Tatiana, Radue, Ernst-Wilhelm, Melanson, Maria

“…Objective This double-blind, placebo-controlled, dose-finding phase IIb study evaluated the efficacy and safety of ponesimod, an oral selective S1P1 receptor…”
Get full text

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies by Freedman, Mark S., Pozzilli, Carlo, Havrdova, Eva Kubala, Lemle, Alexandre, Burcklen, Michel, Larbalestier, Anna, Hennessy, Brian, Sidorenko, Tatiana, Vaclavkova, Andrea, Olsson, Tomas

“…To evaluate the dose-response relationship of 10, 20 and 40-mg ponesimod and long-term efficacy and safety of ponesimod 20 mg using an analysis of combined…”
Get full text

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes by KAPPOS, L, POLMAN, C. H, POHL, C, SANDBRINK, R, FREEDMAN, M. S, EDAN, G, HARTUNG, H. P, MILLER, D. H, MONTALBAN, X, BARKHOF, F, BAUER, L, JAKOBS, P

“…To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple…”
Get full text

Body mass index as a predictor of MS activity and progression among participants in BENEFIT by Manuel Escobar, Juan, Cortese, Marianna, Edan, Gilles, Freedman, Mark S, Hartung, Hans-Peter, Montalbán, Xavier, Sandbrink, Rupert, Radü, E-W, Barkhof, Frederik, Wicklein, Eva-Maria, Kappos, Ludwig, Ascherio, Alberto, Munger, Kassandra L

“…Background: There is a lack of studies on the association between obesity and conversion from a clinically isolated syndrome (CIS) to multiple sclerosis (MS)…”
Get full text

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group by Freedman, Mark S, Bar-Or, Amit, Atkins, Harold L, Karussis, Dimitrios, Frassoni, Francesco, Lazarus, Hillard, Scolding, Neil, Slavin, Shimon, Le Blanc, Katarina, Uccelli, Antonio

“…Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms of repair to the damaged central nervous system. Cell-based…”
Get full text

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis by Uccelli, Antonio, Laroni, Alice, Brundin, Lou, Clanet, Michel, Fernandez, Oscar, Nabavi, Seyed Massood, Muraro, Paolo A, Oliveri, Roberto S, Radue, Ernst W, Sellner, Johann, Soelberg Sorensen, Per, Sormani, Maria Pia, Wuerfel, Jens Thomas, Battaglia, Mario A, Freedman, Mark S

“…Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal…”
Get full text

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS by FREEDMAN, M. S, BAR-OR, A, FERENCZI, L, VERCO, T, OGER, J, TRABOULSEE, A, PATRY, D, YOUNG, C, OLSSON, T, LI, D, HARTUNG, H.-P, KRANTZ, M

“…To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA)…”
Get full text

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide by Wolinsky, Jerry S, Narayana, Ponnada A, Nelson, Flavia, Datta, Sushmita, O’Connor, Paul, Confavreux, Christian, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Truffinet, Philippe, Wang, Lin, Miller, Aaron, Freedman, Mark S

“…Objective: The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance…”
Get full text

Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management by Freedman, Mark S., Gnanapavan, Sharmilee, Booth, Ronald A., Calabresi, Peter A., Khalil, Michael, Kuhle, Jens, Lycke, Jan, Olsson, Tomas

“…Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in…”
Get full text